Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex.

ABSTRACT:

Purpose

Glioblastoma multiforme (GBM) is a devastating disease. Recent studies suggest that the stem cell properties of GBM contribute to the development of therapy resistance.

Experimental design

The expression of Survivin and Ran was evaluated by immunohistochemistry with GBM tissues, and quantitative reverse transcriptase (qRT)-PCR and immunocytochemistry with patient-derived GBM sphere cultures. With a computational structure-based drug design, 11 small-molecule compounds were designed, synthesized, and evaluated as inhibitor candidates for the molecular interaction of Survivin protein. The molecular mechanism of the lead compound, LLP-3, was determined by Western blot, ELISA, in situ proximity ligation assay, and immunocytochemistry. The effects of LLP-3 treatment on GS

SUBMITTER: Guvenc H 

PROVIDER: S-EPMC4295559 | biostudies-literature | 2013 Feb

REPOSITORIES: biostudies-literature